MutS homologue hMSH5: Role in cisplatin-induced DNA damage response

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Tompkins, Joshua D ^a   Wu, Xiling ^a   Her, Chengtao ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

c Abl; Cisplatin; hMSH4; hMSH5; Homologous recombination

Indexed keywords

CISPLATIN; PROTEIN MSH5; PROTEIN MUTS; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; MSH5 PROTEIN, HUMAN;

ARTICLE; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; G2 PHASE CELL CYCLE CHECKPOINT; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; RECOMBINATION REPAIR; RNA INTERFERENCE; CELL LINE; DRUG EFFECT; GENETICS; IMMUNOPRECIPITATION; METABOLISM; PHOSPHORYLATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL CYCLE PROTEINS; CELL LINE; CISPLATIN; DNA BREAKS, DOUBLE-STRANDED; DNA DAMAGE; HUMANS; IMMUNOPRECIPITATION; PHOSPHORYLATION; RNA INTERFERENCE;

EID: 84862795173     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-10     Document Type: Article

References (54)

1. de Vries SS, Baart EB, Dekker M, Siezen A, de Rooij DG, de Boer P, te Riele H. Mouse MutS-like protein Msh5 is required for proper chromosome synapsis in male and female meiosis. Genes Dev 1999, 13:523-531. 10.1101/gad.13.5.523, 316502, 10072381.
2. Edelmann W, Cohen PE, Kneitz B, Winand N, Lia M, Heyer J, Kolodner R, Pollard JW, Kucherlapati R. Mammalian MutS homologue 5 is required for chromosome pairing in meiosis. Nat Genet 1999, 21:123-127. 10.1038/5075, 9916805.
3. Hollingsworth NM, Ponte L, Halsey C. MSH5, a novel MutS homolog, facilitates meiotic reciprocal recombination between homologs in Saccharomyces cerevisiae but not mismatch repair. Genes Dev 1995, 9:1728-1739. 10.1101/gad.9.14.1728, 7622037.
4. Bawa S, Xiao W. A mutation in the MSH5 gene results in alkylation tolerance. Cancer Res 1997, 57:2715-2720.
5. Bawa S, Xiao W. A single amino acid substitution in MSH5 results in DNA alkylation tolerance. Gene 2003, 315:177-182.
6. Rinaldo C, Bazzicalupo P, Ederle S, Hilliard M, La Volpe A. Roles for Caenorhabditis elegans rad-51 in meiosis and in resistance to ionizing radiation during development. Genetics 2002, 160:471-479. 1461995, 11861554.
7. Snowden T, Acharya S, Butz C, Berardini M, Fishel R. hMSH4-hMSH5 recognizes Holliday Junctions and forms a meiosis-specific sliding clamp that embraces homologous chromosomes. Mol Cell 2004, 15:437-451. 10.1016/j.molcel.2004.06.040, 15304223.
8. Kato T, Sato N, Hayama S, Yamabuki T, Ito T, Miyamoto M, Kondo S, Nakamura Y, Daigo Y. Activation of Holliday junction recognizing protein involved in the chromosomal stability and immortality of cancer cells. Cancer Res 2007, 67:8544-8553. 10.1158/0008-5472.CAN-07-1307, 17823411.
9. Lenzi ML, Smith J, Snowden T, Kim M, Fishel R, Poulos BK, Cohen PE. Extreme heterogeneity in the molecular events leading to the establishment of chiasmata during meiosis i in human oocytes. Am J Hum Genet 2005, 76:112-127. 10.1086/427268, 1196414, 15558497.
10. Yi W, Lee TH, Tompkins JD, Zhu F, Wu X, Her C. Physical and functional interaction between hMSH5 and c-Abl. Cancer Res 2006, 66:151-158. 10.1158/0008-5472.CAN-05-3019, 16397227.
11. Her C, Zhao N, Wu X, Tompkins JD. MutS homologues hMSH4 and hMSH5: diverse functional implications in humans. Front Biosci 2007, 12:905-911. 10.2741/2112, 17127347.
12. Sekine H, Ferreira RC, Pan-Hammarstrom Q, Graham RR, Ziemba B, de Vries SS, Liu J, Hippen K, Koeuth T, Ortmann W, et al. Role for Msh5 in the regulation of Ig class switch recombination. Proc Natl Acad Sci USA 2007, 104:7193-7198. 10.1073/pnas.0700815104, 1855370, 17409188.
13. Wang Y, Broderick P, Webb E, Wu X, Vijayakrishnan J, Matakidou A, Qureshi M, Dong Q, Gu X, Chen WV. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 2008, 40:1407-1409. 10.1038/ng.273, 2695928, 18978787.
14. Tompkins JD, Wu X, Chu YL, Her C. Evidence for a direct involvement of hMSH5 in promoting ionizing radiation induced apoptosis. Exp Cell Res 2009, 315:2420-2432. 10.1016/j.yexcr.2009.05.004, 3171649, 19442657.
15. Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci USA 2002, 99:4592-4595. 10.1073/pnas.072067999, 123692, 11904381.
16. Her C, Doggett NA. Cloning, structural characterization, and chromosomal localization of the human orthologue of Saccharomyces cerevisiae MSH5 gene. Genomics 1998, 52:50-61. 10.1006/geno.1998.5374, 9740671.
17. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res 2001, 478:23-43. 10.1016/S0027-5107(01)00141-5, 11406167.
18. Comess KM, Burstyn JN, Essigmann JM, Lippard SJ. Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts. Biochemistry 1992, 31:3975-3990. 10.1021/bi00131a013, 1314653.
19. O'Brien V, Brown R. Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis 2006, 27:682-692.
20. Ciccarelli RB, Solomon MJ, Varshavsky A, Lippard SJ. In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40 chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. Biochemistry 1985, 24:7533-7540. 10.1021/bi00347a005, 3004558.
21. Moggs JG, Szymkowski DE, Yamada M, Karran P, Wood RD. Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts. Nucleic Acids Res 1997, 25:480-491. 10.1093/nar/25.3.480, 146461, 9016585.
22. McHugh PJ, Spanswick VJ, Hartley JA. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2001, 2:483-490. 10.1016/S1470-2045(01)00454-5, 11905724.
23. Nowosielska A, Calmann MA, Zdraveski Z, Essigmann JM, Marinus MG. Spontaneous and cisplatin-induced recombination in Escherichia coli. DNA Repair (Amst) 2004, 3:719-728.
24. Nowosielska A, Marinus MG. Cisplatin induces DNA double-strand break formation in Escherichia coli dam mutants. DNA Repair (Amst) 2005, 4:773-781.
25. Helleday T, Lo J, van Gent DC, Engelward BP. DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst) 2007, 6:923-935.
26. Neyton S, Lespinasse F, Lahaye F, Staccini P, Paquis-Flucklinger V, Santucci-Darmanin S. CRM1-dependent nuclear export and dimerization with hMSH5 contribute to the regulation of hMSH4 subcellular localization. Exp Cell Res 2007, 313:3680-3693. 10.1016/j.yexcr.2007.08.010, 17869244.
27. Lahaye F, Lespinasse F, Staccini P, Palin L, Paquis-Flucklinger V, Santucci-Darmanin S. hMSH5 is a nucleocytoplasmic shuttling protein whose stability depends on its subcellular localization. Nucleic Acids Res 2010, 38:3655-3671. 10.1093/nar/gkq098, 2887964, 20185565.
28. Olive PL, Banath JP. Kinetics of H2AX phosphorylation after exposure to cisplatin. Cytometry B Clin Cytom 2009, 76:79-90.
29. Yi W, Wu X, Lee TH, Doggett NA, Her C. Two variants of MutS homolog hMSH5: prevalence in humans and effects on protein interaction. Biochem Biophys Res Commun 2005, 332:524-532. 10.1016/j.bbrc.2005.04.154, 15907804.
30. Her C, Wu X, Wan W, Doggett NA. Identification and characterization of the mouse MutS homolog 5: Msh5. Mamm Genome 1999, 10:1054-1061. 10.1007/s003359901161, 10556423.
31. Lee TH, Yi W, Griswold MD, Zhu F, Her C. Formation of hMSH4-hMSH5 heterocomplex is a prerequisite for subsequent GPS2 recruitment. DNA Repair (Amst) 2006, 5:32-42.
32. Olive PL. Retention of gammaH2AX foci as an indication of lethal DNA damage. Radiother Oncol 2011,
33. Takata M, Sasaki MS, Tachiiri S, Fukushima T, Sonoda E, Schild D, Thompson LH, Takeda S. Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs. Mol Cell Biol 2001, 21:2858-2866. 10.1128/MCB.21.8.2858-2866.2001, 86915, 11283264.
34. Banath JP, Klokov D, MacPhail SH, Banuelos CA, Olive PL. Residual gammaH2AX foci as an indication of lethal DNA lesions. BMC Cancer 2010, 10:4. 10.1186/1471-2407-10-4, 2819996, 20051134.
35. Boeckman HJ, Trego KS, Turchi JJ. Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining. Mol Cancer Res 2005, 3:277-285. 10.1158/1541-7786.MCR-04-0032, 2432110, 15886299.
36. Dolling JA, Boreham DR, Brown DL, Mitchel RE, Raaphorst GP. Modulation of radiation-induced strand break repair by cisplatin in mammalian cells. Int J Radiat Biol 1998, 74:61-69. 10.1080/095530098141735, 9687976.
37. Pani E, Stojic L, El-Shemerly M, Jiricny J, Ferrari S. Mismatch repair status and the response of human cells to cisplatin. Cell Cycle 2007, 6:1796-1802. 10.4161/cc.6.14.4472, 17622800.
38. Takahashi M, Koi M, Balaguer F, Boland CR, Goel A. MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. J Biol Chem 2011, 286:12157-12165. 10.1074/jbc.M110.198804, 21285347.
39. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996, 56:3087-3090.
40. Drummond JT, Anthoney A, Brown R, Modrich P. Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 1996, 271:19645-19648. 10.1074/jbc.271.33.19645, 8702663.
41. Duckett DR, Drummond JT, Murchie AI, Reardon JT, Sancar A, Lilley DM, Modrich P. Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci USA 1996, 93:6443-6447. 10.1073/pnas.93.13.6443, 39042, 8692834.
42. Mello JA, Acharya S, Fishel R, Essigmann JM. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol 1996, 3:579-589. 10.1016/S1074-5521(96)90149-0, 8807890.
43. Yamada M, O'Regan E, Brown R, Karran P. Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. Nucleic Acids Res 1997, 25:491-496. 10.1093/nar/25.3.491, 146450, 9016586.
44. Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, van der Zee AG, Anthoney DA. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 1997, 15:45-52. 10.1038/sj.onc.1201167, 9233776.
45. Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin TP, Nehme A, Christen RD, Haas M, MacLeod CL, Howell SB. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 1997, 57:1841-1845.
46. Papouli E, Cejka P, Jiricny J. Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells. Cancer Res 2004, 64:3391-3394. 10.1158/0008-5472.CAN-04-0513, 15150090.
47. Watanabe Y, Koi M, Hemmi H, Hoshai H, Noda K. A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer. Br J Cancer 2001, 85:1064-1069. 10.1054/bjoc.2001.2037, 2375095, 11592780.
48. Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999, 18:2335-2341. 10.1038/sj.onc.1202540, 10327053.
49. Samimi G, Fink D, Varki NM, Husain A, Hoskins WJ, Alberts DS, Howell SB. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res 2000, 6:1415-1421.
50. Neher TM, Bodenmiller D, Fitch RW, Jalal S, Turchi JJ. Novel Irreversible Small Molecule Inhibitors of Replication Protein A Display Single Agent Activity and Synergize with Cisplatin. Mol Cancer Ther 2011,
51. Saleh-Gohari N, Helleday T. Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells. Nucleic Acids Res 2004, 32:3683-3688. 10.1093/nar/gkh703, 484186, 15252152.
52. Zhao N, Zhu F, Yuan F, Haick AK, Fukushige S, Gu L, Her C. The interplay between hMLH1 and hMRE11: role in MMR and the effect of hMLH1 mutations. Biochem Biophys Res Commun 2008, 370:338-343. 10.1016/j.bbrc.2008.03.082, 2443822, 18373977.
53. Her C, Wu X, Griswold MD, Zhou F. Human MutS homologue MSH4 physically interacts with von Hippel-Lindau tumor suppressor-binding protein 1. Cancer Res 2003, 63:865-872.
54. Vo AT, Zhu F, Wu X, Yuan F, Gao Y, Gu L, Li GM, Lee TH, Her C. hMRE11 deficiency leads to microsatellite instability and defective DNA mismatch repair. EMBO Rep 2005, 6:438-444. 10.1038/sj.embor.7400392, 1299302, 15864295.